NEIDLE, S. et al. Appl. No. To be assigned US National Phase of PCT/GB03/00102 July 14, 2004

## **AMENDMENTS TO THE CLAIMS:**

This listing of claims will replace all prior versions, and listings, of claims in the application:

1.(original) A compound of the formula:

wherein either:

- (a) K is =O, L is-H, a is a single bond, β is a double bond, γ is a single bond ("acridone"); or:
- (b) K is a 9-substituent, L is absent,  $\alpha$  is a double bond,  $\beta$  is a single bond,  $\gamma$  is a double bond ("acridine");

and wherein:

J<sup>1</sup> is a 2-or 3-substituent; and,

J<sup>2</sup> is a 6-or 7-substituent;

and wherein  $J^1$  and  $J^2$  are each independently a group of the formula:

wherein:

 $R^{N1}$  is independently a nitrogen substituent and is hydrogen,  $C_{1-7}$ alkyl,  $C_{3-20}$ heterocyclyl, or  $C_{5\ 20}$ aryl, and is optionally substituted; and,

NEIDLE, S. et al. Appl. No. To be assigned US National Phase of PCT/GB03/00102 July 14, 2004

W is independently  $C_{1-7}$ alkyl,  $C_{3-20}$ heterocyclyl, or  $C_{5-20}$ aryl, and is optionally substituted;

and wherein, when K is a 9-substituent, K is a group of the formula:

wherein:

R<sup>N2</sup> is independently a nitrogen substituent and is hydrogen, C<sub>1-7</sub> alkyl, C<sub>3-20</sub>heterocyclyl, or C<sub>5-20</sub> aryl, and is optionally substituted; and,

Q is independently  $C_{1-7}$ alkyl,  $C_{3-20}$ heterocyclyl, or  $C_{5-20}$ aryl, and is optionally substituted;

and pharmaceutically acceptable salts, esters, amides, solvates, hydrates, and protected forms thereof.

Claims 2-77 (canceled)